Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma, a late-stage biopharmaceutical company, has announced that the Therapeutics Goods Administration of Australia has designated orBec as an orphan drug for the treatment of patients with gastrointestinal graft-versus-host-disease following allogeneic hematopoietic cell transplantation.
Subscribe to our email newsletter
Christopher Schaber, president and CEO of Dor BioPharma, said: “We are pleased with the Therapeutics Goods Administration’s decision to grant orBec orphan drug designation for the treatment of gastrointestinal graft-versus-host-disease (GI GVHD).
“This bolsters our intellectual property position in Australia, which already includes issued and pending patents covering orBec in GI GVHD. It also potentially provides for a quicker path to regulatory approval in Australia once we have successfully completed our confirmatory Phase III clinical trial of orBec.”